Curanex Pharmaceuticals Inc (NASDAQ:CURX) Short Interest Down 43.2% in July

Curanex Pharmaceuticals Inc (NASDAQ:CURX) saw a large drop in short interest in the month of July. As of July 15th, there was short interest totaling 11,829 shares, a drop of 43.2% from the June 30th total of 20,835 shares. Based on an average trading volume of 81,338 shares, the short-interest ratio is currently 0.1 days. Approximately 0.1% of the company’s stock are sold short.

Hedge Funds Weigh In On Curanex Pharmaceuticals

A hedge fund recently bought a new position in Curanex Pharmaceuticals stock. Citadel Advisors LLC bought a new stake in shares of Curanex Pharmaceuticals Inc (NASDAQ:CURX) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 64,067 shares of the company’s stock, valued at approximately $46,000.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of Curanex Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, May 1st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Curanex Pharmaceuticals Stock Up 0.7%

Shares of NASDAQ:CURX traded up $0.00 on Thursday, hitting $0.20. 3,766 shares of the company traded hands, compared to its average volume of 1,925,999. The stock has a 50 day simple moving average of $0.27 and a 200-day simple moving average of $0.35. The company has a market cap of $5.53 million and a PE ratio of -0.72. Curanex Pharmaceuticals has a 52 week low of $0.18 and a 52 week high of $9.18.

Curanex Pharmaceuticals (NASDAQ:CURX) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.11) earnings per share (EPS) for the quarter.

About Curanex Pharmaceuticals

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.